William Blair Analysts Cut Earnings Estimates for Medtronic

Medtronic plc (NYSE:MDT) – Equities research analysts at William Blair reduced their Q3 2026 earnings per share estimates for Medtronic in a report issued on Tuesday, November 19th. William Blair analyst M. Andrew now expects that the medical technology company will post earnings per share of $1.46 for the quarter, down from their previous estimate of $1.49. The consensus estimate for Medtronic’s current full-year earnings is $5.46 per share. William Blair also issued estimates for Medtronic’s Q4 2026 earnings at $1.68 EPS.

Several other analysts also recently weighed in on MDT. Piper Sandler lifted their price objective on Medtronic from $85.00 to $90.00 and gave the company a “neutral” rating in a report on Wednesday, August 21st. Barclays lifted their price objective on Medtronic from $104.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, August 22nd. Evercore ISI lifted their price objective on Medtronic from $100.00 to $104.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Robert W. Baird cut their target price on Medtronic from $96.00 to $93.00 and set a “neutral” rating on the stock in a research note on Wednesday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Medtronic in a research note on Monday. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $95.19.

Medtronic Stock Performance

MDT stock opened at $84.71 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.84 and a quick ratio of 1.61. The business has a 50-day moving average price of $89.07 and a 200 day moving average price of $84.84. The company has a market capitalization of $108.63 billion, a P/E ratio of 25.90, a PEG ratio of 2.42 and a beta of 0.84. Medtronic has a 1-year low of $75.96 and a 1-year high of $92.68.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, November 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.01. The business had revenue of $8.40 billion during the quarter, compared to the consensus estimate of $8.27 billion. Medtronic had a return on equity of 13.79% and a net margin of 13.00%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period last year, the company earned $1.25 earnings per share.

Institutional Investors Weigh In On Medtronic

A number of large investors have recently modified their holdings of MDT. Fortitude Family Office LLC purchased a new stake in Medtronic in the third quarter valued at approximately $27,000. Highline Wealth Partners LLC purchased a new stake in Medtronic in the third quarter valued at approximately $27,000. Darwin Wealth Management LLC purchased a new stake in Medtronic in the third quarter valued at approximately $27,000. Lynx Investment Advisory purchased a new stake in Medtronic in the second quarter valued at approximately $28,000. Finally, J. Stern & Co. LLP purchased a new stake in Medtronic in the third quarter valued at approximately $30,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.